- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06357026
Phitys I™ Percutaneous Left Ventricular Assist System Study
The Safety and Efficacy of the Percutaneous Left Ventricular Assist System for Intraoperative Circulatory Support During High-risk Percutaneous Coronary Intervention (PCI): a Prospective, Multi-center, Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yang Xu
- Phone Number: +86 021-20788668
- Email: xu_yang@newmed.cn
Study Locations
-
-
Changchun
-
Jilin, Changchun, China
- The Second Hospital of Jilin University
-
Contact:
- Bin Liu
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- The First Affiliated Hospital of Harbin Medical University
-
Contact:
- Yue Li
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Provincial Chest Hospital
-
Contact:
- Yiqiang Yuan
-
-
Hubei
-
Wuhan, Hubei, China
- Renmin Hospital of Wuhan University
-
Contact:
- Hong Jiang
-
-
Hunan
-
Changsha, Hunan, China
- The Second Xiangya Hospital Of Central South University
-
Contact:
- Shenghua Zhou
-
-
Liaoning
-
Shenyang, Liaoning, China
- General Hospital of Northern Theater Command
-
Contact:
- Yaling Han
-
-
Shanghai
-
Shanghai, Shanghai, China
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
Contact:
- Li Zhang
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China Hospital, Sichuan University
-
Contact:
- Mao Chen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years old≤ patient age ≤90 years old AND patient is not in pregnancy or lactation;
- Patients who have been evaluated by two or more cardiovascular surgeons as unsuitable for conventional surgery; or patients who have refused conventional surgery after adequate communication from the surgeon and who are at high risk for conventional surgery;
Left Ventricular Ejection Fraction (LVEF) ≤ 35% AND at least one of the following criteria:
- Intervention on the last patent coronary conduit, or
- Intervention on an unprotected left main coronary artery Or b) LVEF ≤ 30% and intervention in patient presenting with triple vessel disease.
- Patient who can understand the purpose of the trial and volunteer to participate in, sign the informed consent form and are willing to accept relevant examinations and clinical follow-ups.
Exclusion Criteria:
- Pre-procedure cardiac arrest within 24 hours of enrolment requiring CPR;
- Pre-procedure ST-segment myocardial infarction within 24 hours of enrolment;
- Patient is in cardiogenic shock;
- Mural thrombus in the left ventricle;
- Post-infarction ventricular septal rupture, or atrial septal or ventricular septal defects;
- The presence of mechanical aortic or mitral valve or heart constrictive device;
- The presence of aortic stenosis (aortic orifice area ≤1.5cm²);
- The presence of moderate to severe aortic or mitral or tricuspid insufficiency;
- The presence of severe peripheral vascular disease that would preclude the placement of the percutaneous mechanical circulatory assist device;
- Severe aortic diseases such as aortic dissection and aortic aneurysm;
- Active infective endocarditis or other active infections;
- Chronic renal insufficiency (creatinine clearance≤30ml/min);
- Liver dysfunction (elevation of liver enzymes and bilirubin levels to ≥3xULN or INR≥2);
- The presence of uncorrectable abnormal coagulation (platelet count≤75,000/mm^3 or INR≥2.0 or fibrinogen≤1.50 g/l);
- The presence of uncorrected moderate to severe anemia (hemoglobin <90 g/L);
- History of stroke or TIA within 1 month of enrolment;
- Allergy or intolerance to contrast media, anticoagulant and antiplatelet drugs (e.g., bivalirudin, low molecular heparin, aspirin, clopidogrel, Ticagrelor, etc.);
- Participation in clinical trials of other drugs or medical devices prior to enrollment that have not yet reached the primary outcome of research;
- Patient with poor compliance and could not complete the study as required determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: percutaneous left ventricular assist system
Subjects with coronary artery disease receiving high-risk PCI will be supported by Percutaneous Ventricular Assist System during the procedure.
|
Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.
|
Active Comparator: intra-aortic balloon pump (IABP)
Subjects with coronary artery disease receiving high-risk PCI will be supported by IABP during the procedure.
|
IABP provides intraoperative circulatory support during high-risk PCI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of freedom from major adverse cardiovascular and cerebrovascular events (MACCE)
Time Frame: 30 days after procedure
|
MACCE defined as death, myocardial infarction, stroke, and target vessel revascularization.
|
30 days after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of death
Time Frame: 30 days, 90 days after procedure
|
Rate of all-cause death during the trial.
|
30 days, 90 days after procedure
|
Incidence of myocardial infarction
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with myocardial infarction during the trial.
|
30 days, 90 days after procedure
|
Incidence of stroke
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with stroke during the trial.
|
30 days, 90 days after procedure
|
Incidence of target vessel revascularization
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with target vessel revascularization during the trial.
|
30 days, 90 days after procedure
|
Incidence of need for cardiac operation or thoracic or abdominal vascular operation or vascular operation for limb ischemia
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with unplanned cardiac operation or thoracic or abdominal vascular operation or vascular operation for limb ischemia during the trial.
|
30 days, 90 days after procedure
|
Incidence of acute kidney injury
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with acute kidney injury during the trial.
|
30 days, 90 days after procedure
|
Incidence of cardiopulmonary resuscitation or ventricular arrhythmia requiring cardioversion
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with cardiopulmonary resuscitation or ventricular arrhythmia requiring cardioversion during the trial.
|
30 days, 90 days after procedure
|
Incidence of increasing in aortic insufficiency by more than one grade
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with increasing in aortic insufficiency by more than one grade during the trial.
|
30 days, 90 days after procedure
|
Incidence of severe hypotension
Time Frame: 30 days, 90 days after procedure
|
Rate of patients with severe hypotension during the trial.
Severe hypotension defined as systolic blood pressure or augmented diastolic pressure (whichever is greater) <90 mmHg for ≥5 min requiring inotropic/pressor medications or IV fluid.
|
30 days, 90 days after procedure
|
Incidence of failure to achieve angiographic success
Time Frame: 30 days, 90 days after procedure
|
Rate of failure to achieve angiographic success during the trial.
Angiographic success defined as residual stenosis <30% after stent implantation.
|
30 days, 90 days after procedure
|
Incidence of freedom from major adverse cardiovascular and cerebrovascular events (MACCE)
Time Frame: 90 days after procedure
|
Rate of patients with freedom from major adverse cardiovascular and cerebrovascular events (MACCE) during the trial. MACCE defined as death, myocardial infarction, stroke, and target vessel revascularization. |
90 days after procedure
|
Hemodynamic support success rate during PCI procedure
Time Frame: During procedure
|
Hemodynamic support success is defined as
|
During procedure
|
Technical success rate
Time Frame: Immediately after procedure
|
Technical success is defined as (1) Hemodynamic support success; (2) Coronary revascularization success (defined as ①residual stenosis <30% after coronary stent implantation; ②restoration of TIMI anterograde flow of II or III).
|
Immediately after procedure
|
Procedural success rate
Time Frame: Immediately after procedure
|
Procedure success is defined as (1) Technical success; (2) Freedom from serious in-hospital procedural complications
|
Immediately after procedure
|
Change in LVEF compared to baseline
Time Frame: 30 days, 90 days after procedure
|
LVEF is assessed at 30 days, 90 days after procedure, and compared to baseline.
|
30 days, 90 days after procedure
|
Improvement in cardiac function
Time Frame: 30 days, 90 days after procedure
|
Cardiac function is evaluated based on NYHA classification and compared to baseline. New York Heart Association (NYHA) Functional Classification includes four categories(CLASS I to CLASS IV, higher class mean a worse outcome) based on physical activity limitations. |
30 days, 90 days after procedure
|
Evaluation of Experimental device performance
Time Frame: Immediately after procedure
|
Performance evaluation includes the catheter pump and extracorporeal control device (For each assessment: 1-10 points;1=worst, 5=moderate, 10=best).
|
Immediately after procedure
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yaling Han, The General Hospital of Northern Theater Command
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Phitys I -2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Percutaneous Ventricular Assist System(Phigine Medical)
-
Shenzhen Core Medical Technology CO.,LTD.Recruiting
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Abbott Medical DevicesThoratec CorporationCompletedCardiomyopathies | Ventricular Dysfunction | Heart Failure, CongestiveUnited States, Canada
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Abbott Medical DevicesThoratec CorporationCompletedHeart FailureUnited States
-
Abbott Medical DevicesThoratec CorporationWithdrawn
-
Shenzhen Core Medical Technology CO.,LTD.Not yet recruiting
-
Abbott Medical DevicesThoratec Corporation; KCRI; Center for Life Sciences; EmergoCompletedAdvanced Refractory Left Ventricular Heart FailureGermany, Australia, Austria, Canada, Czechia, Kazakhstan
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruiting
-
Shenzhen Core Medical Technology CO.,LTD.Completed